Focused on the development and commercialization of novel vaccines
HilleVax is a Frazier-founded company focused on the development and commercialization of novel vaccine candidates. The company has licensed rights from Takeda to develop and commercialize its norovirus vaccine candidate worldwide outside of Japan. HIL-214 is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
